Aurobindo Pharma rises as its arm incorporates wholly owned subsidiary in South America
Aurobindo Pharma is currently trading at Rs. 1111.90, up by 10.90 points or 0.99% from its previous closing of Rs. 1101.00 on the BSE.
The scrip opened at Rs. 1112.00 and has touched a high and low of Rs. 1120.00 and Rs. 1104.40 respectively. So far 12509 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1482.25 on 22-Oct-2024 and a 52 week low of Rs. 994.35 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 1120.00 and Rs. 1093.00 respectively. The current market cap of the company is Rs. 64596.76 crore.
The promoters holding in the company stood at 51.82%, while Institutions and Non-Institutions held 41.81% and 6.38% respectively.
Aurobindo Pharma’s wholly owned subsidiary -- Helix Healthcare B.V, has incorporated a new wholly owned subsidiary in Chile, South America by the name of Aurobindo Pharma Chile SpA. The object of incorporation of this wholly owned subsidiary is to expand the Pharmaceutical Products business in Ch
Further, the company’s wholly owned stepdown subsidiary -- Eugia Pharma B.V, has also incorporated a new wholly owned subsidiary in Chile by the name of Eugia Pharma Chile SpA.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
